Large-scale production and purification of VLP-based vaccines
Journal of invertebrate pathology, 2011•Elsevier
Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These
innovative biopharmaceuticals present the remarkable advantages of closely mimicking the
three-dimensional nature of an actual virus while lacking the virus genome packaged inside
its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to
inactivated or live attenuated viral vaccines. With the advent of successful cases of approved
VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to …
innovative biopharmaceuticals present the remarkable advantages of closely mimicking the
three-dimensional nature of an actual virus while lacking the virus genome packaged inside
its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to
inactivated or live attenuated viral vaccines. With the advent of successful cases of approved
VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to …
Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果